An alphavirus-based therapeutic cancer vaccine: from design to clinical trial

Amrita Singh1 · Georgia Koutsoumpli1 · Stephanie van de Wall1,2 · Toos Daemen1

Received: 2 May 2018 / Accepted: 9 November 2018 / Published online: 21 November 2018
© The Author(s) 2018

Abstract
Cancer immunotherapy has greatly advanced in recent years. Most immunotherapeutic strategies are based on the use of immune checkpoint blockade to unleash antitumor immune responses or on the induction or adoptive transfer of immune effector cells. We aim to develop therapeutic vaccines based on recombinant Semliki Forest virus vectors to induce tumor-specific effector immune cells. In this review, we describe our ongoing work on SFV-based vaccines targeted against human papillomavirus- and hepatitis C virus-related infections and malignancies, focusing on design, delivery, combination strategies, preclinical efficacy and product development for a first-in-man clinical trial with an HPV-specific vaccine.

Keywords Therapeutic vaccine · Recombinant Semliki Forest virus vector · Hepatitis C virus · Human papillomavirus · Cervical intraepithelial neoplasia · PIVAC 17

Introduction
Immunotherapy, which was recognized as the breakthrough of the year 2013, has given a new direction to the development of anti-cancer therapies. Cancer immunotherapies aim to stimulate or unleash the patient’s immune system to attack cancers. These strategies are primarily based on antibodies targeting immune checkpoints, tumor-specific antibodies, a diversity of adoptive cell therapies, therapeutic vaccines and immunomodulators [1, 2]. Therapeutic vaccines include synthetic peptides, recombinant proteins, nucleic acids, autologous cells and bacterial or recombinant viral vectors. Recombinant viral vector vaccination is attractive above all others as it generally offers high infection efficiency, antigen

Abbreviations
Ad  Adenovirus
APC  Antigen-presenting cell
CIN  Cervical intraepithelial neoplasia
CTL  Cytotoxic T lymphocyte
CTLA-4  Cytotoxic T lymphocyte antigen-4
DREP  DNA replicon
ER  Endoplasmic reticulum
GITR  Glucocorticoid-induced TNFR-related protein
GMP  Good manufacturing practice
HCV  Hepatitis C virus
HPV  Human papillomavirus
HSIL  High-grade squamous intraepithelial lesion
IP  Infectious particles
MDSC  Myeloid-derived suppressor cell
nsPs  Non-structural proteins
PBMC  Peripheral blood mononuclear cell
PD-1  Programmed cell death protein-1
PRR  Pattern recognition receptor
rSFV  Recombinant SFV
SFV  Semliki Forest virus
SIN  Sindbis virus
Treg  Regulatory T cell
VEE  Venezuelan equine encephalitis virus
VRP  Virus-like replicon particles
expression and immunogenicity. Vector-based vaccines have been generated from a diversity of viruses including adenoviruses, adeno-associated virus, vaccinia viruses, poxviruses and alphaviruses [2]. Our work in recent years has focused on developing therapeutic cancer vaccines based on Semliki Forest virus (SFV) replicon particles for the treatment of human papillomavirus (HPV)- and hepatitis C virus (HCV)-related infections/malignancies.

This review aims to summarize the development of our SFV-based cancer vaccines. We will describe the various preclinical evaluation studies conducted in our lab, which ultimately led to the first-in-man trial of an SFV-based vaccine in 2017.

The Semliki Forest virus replicon vector system

The most frequently used alphavirus vectors are derived from SFV [3], Venezuelan Equine Encephalitis virus (VEE) [4] and Sindbis virus (SIN) [5]. Alphaviruses are enveloped viruses containing a positive strand RNA genome of about 11–12 kb, coding for the non-structural replicase and the structural proteins. The genomic RNA has a methylated nucleotide cap at the 5’-terminus and a polyadenylated tail at the 3’-terminus, resembling cellular mRNA. Alphaviruses form spherical enveloped particles (65–70 nm diameter) with their genome contained within an icosahedral capsid. The envelope contains two major glycoproteins, E1 and E2, forming heterologous spikes that act as attachment proteins. After virus attachment and entry into the cell, gene expression and replication take place within the cytoplasm [6, 7].

The SFV-based replicon vector system was first developed by Peter Liljestrom and Henrik Garoff at the Karolinska Institute, Stockholm [3]. Additional SFV-based vectors were developed with improved biosafety [8, 9]. The recombinant SFV (rSFV) vector RNA codes for the viral replicase while the sequence encoding the structural proteins of SFV can be replaced by a gene of interest. The recombinant virus particles called replicons, due to their self-replicating nature, are obtained by co-transfection of cells with the vector RNA and the helper RNA encoding the structural proteins [10]. As the helper RNA does not express the replicase, amplification of both the vector and the helper RNAs is driven by the replicase of the vector RNA. The capsid protein recognizes the packaging signal located in the replicase region of the vector RNA and packs only the recombinant vector RNA into nucleocapsids. The envelope/spike proteins migrate to the plasma membrane where they interact with nucleocapsids leading to the formation and subsequent budding of virus replicon particles (Fig. 1). Since SFV vectors are engineered such that the replicon particles lack sequences coding for the viral structural proteins, they are capable of only one round of infection and replication. SFV RNA does not integrate into the host genome and since infection with SFV induces apoptosis, this minimizes the risk of constitutive expression of heterologous proteins (antigen of interest). For clinical translation, increased biosafety is required to further reduce the risk of recombination of the two RNAs that could lead to the formation of replication-competent virus. For this, Smerdou and Liljestrom developed the so-called two-helper system in which the structural genes coding for the spike and capsid proteins are placed on two separate helper RNA constructs [9].

Following immunization, rSFV particles infect a broad range of cells that undergo apoptosis. Thereafter, apoptotic bodies containing antigen are taken up by antigen-presenting cells (APCs) which can then present to CD8⁺ and CD4⁺ T cells leading to the generation of antigen-specific cellular immune responses. A major difference between VEE and SFV replicon particles is that VEE replicon particles preferentially target dendritic cells resulting in direct MHC class I presentation of the antigen, whereas SFV replicon particles cannot translate their RNA in APCs but induce CTL response via cross-priming [11, 12]. Infection with SFV and other alphaviruses leads to the formation of double-stranded RNA (dsRNA) intermediates, which are recognized as “danger signals” by pattern recognition receptors such as RIG-I and trigger production of type I interferons [13, 14]. Therefore, recombinant vector vaccines based on alphaviruses are capable of activating both the innate and the adaptive arms of the immune system.

Another type of SFV-based vector that Liljestrom and colleagues developed is the DNA replicon (DREP) [15]. This vector system combines the advantages of the SFV replicon vector with that of a DNA vaccine, which are ease of production and cost-effectiveness. The plasmid contains cDNA sequences of the SFV replicase, where the transcription of the viral replicon is under the control of a CMV promoter and where the mRNA coding for the foreign antigens is expressed from an internal viral promoter on the replicon RNA. Upon transfection with DREP plasmid DNA, the DNA is transported to the nucleus where the RNA polymerase drives its transcription to RNA. The recombinant mRNA transcript is then transported to the cytoplasm, where the translation of the SFV replicase directs replication and high production of the foreign protein in a way similar to that by SFV replicons [10].
HPV infection is associated with over 99% cases of cervical cancer, the fourth most common cancer type among women worldwide [16, 17]. HPV infection is also a causal agent of other genital cancers such as penile, vaginal, vulvar and anal but also an increasing percentage of oropharyngeal cancers. The high-risk HPV types 16 and 18 are the most common and are associated with approximately 70% of cervical cancer cases. In general, the virus is cleared but if the infection persists, low- to high-grade cervical intraepithelial neoplasia (CIN) and ultimately cervical carcinoma may develop. Malignant transformation of epithelial cells is accomplished through integration of HPV viral DNA genome into the host genome with the disruption of genes including E2, a negative regulator of the HPV oncoproteins E6 and E7. High expression of these oncoproteins in transformed cells is responsible for the induction and maintenance of cellular transformation.

Currently, there are three prophylactic HPV vaccines available: Cervarix, Gardasil and Gardasil-9 [18]. These vaccines effectively induce HPV type-specific antibodies to prevent the most prevalent high-risk HPV infections. Despite the availability of these highly effective prophylactic HPV vaccines, over 85% of young adolescent females worldwide...
are not vaccinated [19], either because an HPV vaccine is not provided in a national vaccination program in many low- or middle-income countries or because of fear of side-effects or opposition to vaccination.

In patients with (pre)malignant cervical cancer, cellular and humoral responses are observed, but they are not sufficient to eliminate HPV-transformed cells [20]. A therapeutic vaccine that is able to induce strong cellular immune response against HPV-transformed cells is therefore highly desirable. Since the viral oncoproteins E6 and E7 of HPV are constitutively expressed in transformed cells, they serve as ideal targets for immunotherapy against HPV-induced lesions or malignancies. We first generated an SFV vector expressing the E6 and E7 protein of HPV16 as separate proteins, rSFVE6E7. The replicon particle vaccine based on this vector induced moderate immune responses in a murine model of cervical cancer with TC-1 tumors [21]. To enhance this response, we inserted the first 34 amino acid residues of the capsid gene of SFV, which functions as a translational enhancer [22], in front of the gene coding for a fusion protein of E6 and E7. Thus, a recombinant SFV vector expressing high levels of a stable fusion protein of HPV16 E6 and E7 was generated, termed rSFVe6,7 [23]. We demonstrated that rSFVe6E7 replicon particles could induce more potent anti-tumor responses than the initial vaccine rSFVE6E7, leading to the complete eradication of established TC-1 tumors. Furthermore, tumor rechallenge studies demonstrated long-term protection. When previously immunized mice were rechallenged with tumor cells after 3 or 6 months, the mice were still protected from tumor outgrowth without another round of immunization and high levels of CTL activity could be measured even up to 11 months after immunization [23, 24]. rSFVe6,7 vaccination could also break immune tolerance in HPV16-transgenic mice [25].

Various immunotherapeutic approaches use viral vector-based systems for immunization against tumors. The adenovirus (Ad) system is one of the most widely used viral vector system, which has also been extensively studied in human trials [26–29]. We therefore compared the efficacy of a recombinant replication-defective Ad (rAd) vaccine expressing the fusion protein of E6 and E7 with the rSFVe6,7 vaccine. We found that prime-boosting with rSFVeE6,7 resulted in higher CTL activity and anti-tumor activity compared to that with rAdeE6,7, even with 100- to 1000-fold lower doses compared to the adenoviral vector [30]. Part of this result can be ascribed to the fact that the low dose of rSFVeE6,7 required to induce an optimal immune response (<10⁶ infectious particles), generated relatively low levels of SFV-neutralizing antibodies that did not prohibit the responsiveness to a booster immunization. The levels of neutralizing antibodies elicited upon rAdeE6,7 immunization however completely blocked antigen expression and a booster response. Vector-specific immunity against adenoviral vectors are extensively studied and strategies are being developed to reduce anti-Ad immunity to improve their efficacy as gene delivery system [31, 32].

**Therapeutic hepatitis C virus vaccines**

Hepatitis C virus (HCV) is a human tumor-associated virus that is transmitted by blood and mainly infects the liver. The majority of hepatitis C virus-infected patients (>70%) do not clear the infection naturally and develop chronic hepatitis, which is associated with the development of liver cirrhosis, liver failure and hepatocellular carcinoma [33]. The standard-of-care treatment for HCV infection in developed countries is based on a combination of very effective antiviral drugs. Although these drugs are highly potent, they are very expensive, may induce resistance and are not widely available. It is also important to note that antiviral treatments aim only at inhibiting HCV replication, but not at inducing HCV-specific T-cell responses and protective immunity, which has been reported to be crucial for the eradication of HCV-infected cells.

In patients with chronic HCV infection, a poor and narrow-spectrum cellular immune response against HCV is often observed while in patients who recovered from acute infection, the immune responses are broader. Thus, boosting the host’s immune response against multiple antigenic epitopes would theoretically be a valid strategy to eradicate persisting viruses and halt associated liver diseases. In the context of hepatitis C virus (HCV) infection, the non-structural proteins (nsPs) of HCV, which are considered to be immunogenic and genetically conserved, are identified as promising targets for vaccine development. With a view to broaden the spectrum of T-cell responses [34], a transgene coding the entire non-structural region of HCV could allow for responses against subdominant epitopes as well, contributing to a wider T-cell repertoire [35].

We therefore explored the possibility of expressing the HCV nsPs in the rSFV vector to promote the generation of HCV-specific and broad-spectrum T-cell responses. Incorporation of the major part of the nsPs of HCV, as large as 6.1 kb, did not affect the immunogenicity of the vaccine. We showed that rSFV vectors expressing HCV NS3/4A (rSFVeNS3/4A) or all nsPs of HCV (rSFVeNS2*-5B') were capable of inducing strong NS3-specific CD8+ T-cell responses, although the response was slightly lower with rSFVeNS2*-5B' [36]. Both vectors induced polyfunctional CD8+ T cells, exhibited HCV-specific cytolytic activity both in vitro as well as in vivo and induced delay in tumor growth.

Taken together, preclinical evaluation of replication-deficient rSFV vectors demonstrated the ability to induce strong effector and memory CTL responses in immunocompetent as well as immune-tolerant mice and to eradicate
pre-established HPV-transformed tumors and HCV-infected cells.

**Anti-vector responses**

As previously mentioned, immunization with replicon viral particles may induce vector-specific immunity, which in turn could influence the efficacy of subsequent booster immunizations. We investigated the effect of vector-specific immune responses on transgene expression and CTL activation by rSFV. We demonstrated that passively transferred SFV-neutralizing antibodies did not prohibit transgene-specific CTL responses, despite the fact that the transgene expression was reduced, albeit not to the level observed with adenoviral booster injections [30, 37]. On the other hand, priming with irrelevant rSFV reduced transgene expression upon subsequent administration of rSFV and inhibited CTL induction due to vector-specific responses, which could be reversed with the co-administration of a relevant antigen (E7-virosomes) at priming. Incorporating an E7-protein antigen along with irrelevant rSFV and then boosting with rSFVeE6,7, induced a similar percentage of E7-specific CTLs as prime-boost immunization with rSFVeE6,7. This points towards a possible role of T-cell competition as a mechanism by which vector-specific immunity interferes with transgene-specific CTL induction. This study confirmed that virus-neutralizing antibodies or vector-specific CTLs do not prohibit the boosting efficacy of rSFV in homologous prime-boost immunizations and rather T-cell competition has a stimulatory effect in such regimens [37]. Yet, SFV-based vaccines have also been successfully used in heterologous combinations with other vaccines [38–42].

**Antigen design**

As the immunogenicity of rSFV relies on cross-priming, the protein of interest should not be (completely) degraded before being processed by antigen-presenting cells. As described above, expression of a more stable fusion protein of E6 and E7 induced higher immune responses compared to the vaccine expressing the E6 and E7 proteins separately [21, 23, 24]. With the aim of further improving the efficacy of our vaccine, we assessed the potential of the replicon particles expressing the HPV16 E6,7 fusion protein or E7SH (a shuffled version of the E7 protein) coupled with helper T-cell epitopes and an ER targeting signal (sigHELP-KDEL), a strategy which successfully improved the efficacy of DNA vaccines [43, 44]. Immunization with both rSFVe-sigHELP-E6,7-KDEL and rSFVe-sigHELP-E7SH-KDEL augmented E7-specific T-cell responses as compared to the corresponding parent vectors. A suboptimal dose of rSFVe-sigHELP-E6,7-KDEL significantly enhanced the anti-tumor responses compared to rSFVeE6,7. Strong memory responses were generated providing protective immunity to the mice against formation of TC-1 tumors.

Inclusion of helper T epitopes and an ER targeting signal further increased the immunogenicity of our HPV vaccines, which was likely due to enhanced protein stability and rendered therapeutic as well as prophylactic immunity with a suboptimal dose of the vaccine [45].

**Delivery routes and methods**

The route of immunization influences vaccine efficacy. We demonstrated that subcutaneous (s.c.) injection of the vector vaccine elicits potent CTL and anti-tumor responses [24]. We further explored different routes of immunization to determine their influence on the degree of vaccine-induced immune response. We demonstrated that these responses were strongly augmented with i.v. (intravenous) and i.m. (intra-muscular) administrations. Although CTL activity was induced upon i.p. (intraperitoneal) and s.c. immunizations, i.v. and i.m. induced much higher CTL frequencies. We also compared i.m. vs i.v. immunization with two suboptimal treatment regimens and concluded that both i.m. and i.v. administrations are equally effective in generating anti-tumor responses [46].

Besides the above-mentioned delivery routes, we examined intra-dermal delivery by means of tattooing. The skin, being rich in APCs, such as Langerhans cells and dermal dendritic cells, is an attractive site for immunization. Tattooing has been mostly described for DNA- and peptide-based vaccines [47–50]. We compared tattoo delivery vs intra-muscular administration of rSFVeE6,7 and found that despite having a tenfold lower overall transgene expression (injection site and draining lymph nodes), tattooing induced similar levels of immune responses in comparison with i.m. delivery of the replicon particles [51]. This delivery method resulted in potent therapeutic anti-tumor response and stimulated long-lasting memory T cells, establishing high immunostimulatory potential of intra-dermal delivery with regard to recombinant SFV vector vaccines.

Following on this route, we generated an HPV16 E6,7 vaccine based on the DREP vector as described above [15] and compared it with a conventional DNA vaccine [52]. The DNA vaccines were administered intra-dermally followed by in vivo electroporation [53, 54] resulting in strong anti-tumor effects with the DREP vaccine when compared with the conventional DNA vaccine pVAX. Upon administration of equimolar doses of DREP and pVAX, we found that DREP strongly enhanced the expression of the protein and high percentages of E7-specific CD8+ T cells were induced, which rendered effective anti-tumor immunity compared to
pVAX. Remarkably, even with a dose 1000-fold lower than that of the conventional DNA vaccine, potent anti-tumor efficacy was observed [52]. On the whole, intra-dermal delivery of DREP along with electroporation as a method of augmenting its efficacy could be a promising alternative of vaccine administration for favorable clinical outcome.

**Combination strategies**

Tumors adopt various mechanisms to evade the immune system such as immune-suppressive cells, upregulation of inhibitory signals such as PD-1 [55], CTLA-4 [56], etc. Therefore, it would be beneficial to target these mechanisms to avert their influence on anti-tumor immunity and improve the suppressive tumor microenvironment. With the purpose of enhancing the efficacy of therapeutic immunization with rSFVeE6,7, the next step was to combine the vaccine with strategies that can modulate the tumor environment.

We investigated two immune-suppressive cell populations, regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). In patients with cervical intraepithelial neoplasia (CIN) and cervical cancer, increased frequencies and immunosuppressive activity of Tregs were observed [57]. Furthermore, therapeutic immunization with different vaccines has been shown to increase numbers of Tregs [58, 59]. In the TC-1 model, we observed that rSFVeE6,7 immunization neither led to Treg expansion nor did it affect Treg activity. Additionally, Treg depletion did not enhance the efficacy of the vaccine, implying that in this model, the presence of Tregs has no influence on rSFV-induced immune responses [60].

Radiation therapy using ionizing radiation is a standard treatment for many types of cancer, used most frequently in combination with surgery or chemotherapy. Local tumor irradiation results in the release of tumor antigens and upregulation of MHC I/II, cytokines and chemokines involved in recruitment of T cells to the tumor [61–63]. With an aim to increase T cell homing into the tumor, we combined local tumor irradiation with the rSFVeE6,7 vaccine. In the mouse model, local low-dose tumor irradiation indeed increased homing of antigen-specific CD8+ T cells into tumors. When tumor-bearing mice were immunized 1 day following irradiation, this effect was further amplified as compared to irradiation or immunization alone. Concurrently however, irradiation also increased the number of intratumoral MDSCs. Since immunization with rSFV did not further increase the number of MDSCs, the ratio of antigen-specific CD8+ T cells to MDSCs in tumors increased 85-fold as compared to the control. The mRNA expression levels of chemokines and their corresponding ligands, such as CCR2 and CCL2, CXCR6 and CCL16, were up-regulated upon irradiation which most likely attributed to homing of different immune cell populations to the tumor. On the whole, this treatment regimen led to a strong increase in the ratio of immune effector cells to immune-suppressive cells, thus skewing towards a more anti-tumor microenvironment [64].

Accumulation of MDSCs in lymphoid organs and tumors is associated with several pathological conditions such as cancer, inflammation and chronic infection [65]. MDSCs are potent suppressors of T-cell responses and to overcome their immune-suppressive activity, we utilized a receptor tyrosine kinase inhibitor, sunitinib malate, due to its capacity to selectively deplete MDSCs and block tumor angiogenesis [66]. We first tested the effect of sunitinib on the levels of MDSCs and observed a dose-dependent decrease in tumor, spleen and circulating blood [67]. Concurrently, sunitinib dose-dependently increased both intratumoral as well as intrasplenic CD8+ T cells accompanied with enhanced activation. This was further enhanced on combined treatment of sunitinib with rSFV immunization compared to either treatment alone. The ratio of E7-specific CD8+ T cells to MDSCs increased 12.5-fold in comparison with immunization alone and enhanced tumor regression [67]. These results suggest that this combination therapy could be further investigated as a promising approach to improve clinical outcome.

The next step was to combine the above-mentioned strategies, uniting the benefits of single low-dose local tumor irradiation with the therapeutic recombinant SFV-based cancer vaccine and sunitinib [68]. The triple treatment induced the most potent MDSC depletion compared to sunitinib alone. Synchronously, the triple treatment caused an increase in activated and degranulating intratumoral CD8+ T cells and further boosted E7-specific CD8+ T cells. The triple treatment strongly enhanced the ratio of E7-specific CD8+ T cells to MDSCs in tumors with a striking 10,000-fold increase compared to the control tumors. Altogether, the trimodal treatment was successful in blocking tumor development, subsequently leading to 100% tumor-free survival of tumor-bearing mice [68]. The results from this study further strengthen the rationale of employing different treatment modalities to refine cancer immunotherapeutic approaches and bring them closer to the clinic.

With the advent of immune checkpoint blockade, the use of monoclonal antibodies targeting several checkpoint molecules such as PD-1 and CTLA-4, has garnered much interest in cancer immunotherapy. Rice et al. demonstrated that immunotherapy with an adenoviral vector vaccine, encoding the HPV16 E6 and E7 genes, in combination with PD-1 checkpoint inhibition resulted in delayed tumor growth and a significant improvement in survival compared to the controls [69]. Another study by Mkrtichyan and colleagues showed that PD-1 blockade synergizes with depletion of Tregs by low-dose cyclophosphamide in enhancing the therapeutic efficacy of the HPV16 peptide vaccine [70]. A more recent strategy is the dual approach
of targeting both inhibitory as well stimulatory molecules. The triple combination of targeting GITR, PD-1 blockade and peptide vaccine induced complete regression in half of the mice, substantially enhancing the anti-tumor immunity [71]. Taking cue from such studies, it would be interesting to investigate the anti-tumor potency of this kind of combination therapy with our vaccine.

Product and process development

Promising results from our preclinical studies motivated us to test this vaccine in a first-in-man phase I clinical trial. The clinical grade Vvax001 was produced at the Unit Biotech and ATMPs of the Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen. For application in the trial, the major concern was the scalable production of a clinical batch of rSFVeE6,7, which we named Vvax001. The production comprised electroporation with three different RNAs, using the two-helper system [9] and harvest of the produced viral particles from cultures of electroporated cells. This production process required optimization with respect to safety, scalability and translation to good manufacturing practice (GMP). Vero cells, approved for GMP production, were chosen for the production of the clinical batch (two-helper system). A number of conditions were tested for scalability including different electroporation conditions, optimal temperature and time for harvesting virus after transfection and percentage of fetal bovine serum (FBS). Using the optimized protocol, viral titers of the order 10^8–10^9 infectious particles (IP)/ml could be achieved.

A toxicity study was performed in female C57/B16 mice using a toxicology batch of Vvax001 produced in a process that was identical to the production process of the clinical grade batch of Vvax001. In addition, tissue distribution and persistence was assessed following a single intra-muscular administration of the highest dose to be tested in subjects, i.e., 5×10^8 IP. No adverse effects were observed in any of the treated animals for the parameters examined. All the immunized mice had HPV16 E7-specific CD8^+ T cells. Bio-distribution/persistence study revealed that the majority of the Vvax001 RNA expressing E6 and E7 of HPV16 was localized at the injection site and was detectable until day 10, which was thereafter rapidly cleared from all tissues. Immunogenicity of the clinical batch with respect to CTL induction and anti-tumor responses was comparable to that of the rSFVeE6,7 vaccine used previously for all preclinical studies. This ‘preclinical’ vaccine was produced on baby hamster kidney cells (BHK-21) using the one-helper system. Altogether, the toxicity and immunization studies attested that the clinical grade Vvax001 was ready for use in the trial.

Clinical trial

Several clinical trials with VEE-based vaccines have been conducted [72–74], whereas SFV- and SIN-based vector vaccines are yet to be tested in clinic. For example, encouraging results were obtained from a phase I/II clinical trial, conducted to evaluate the safety and CEA-specific immune responses to the immunizations with a VEE replicon particle vaccine, CEA(6D)-VRP (AVX701), in patients with advanced cancer. Repeated administration of the vaccine induced clinically relevant CEA-specific T cell and antibody responses, despite the generation of neutralizing antibodies against the VRP and high levels of Tregs in PBMCs. In addition, patients with CEA-specific T-cell responses appeared to have better survival. Clinical response observed in some patients was attributed to higher dose of VRP-CEA [75].

With respect to HPV, several types of immunotherapeutic approaches aimed at inducing robust cell-mediated responses against HPV-driven infections and malignancies have been developed and tested for safety and efficacy in clinical trials. A phase II randomized, placebo-controlled clinical trial of VGX-3100, a synthetic DNA vaccine targeting HPV 16 and 18 E6 and E7 proteins, in women with CIN2/3 resulted in significantly higher histopathological regression and viral clearance following VGX-3100 vaccination as compared to placebo [76]. This vaccine is currently being investigated in a phase III trial in women with high-grade squamous intraepithelial lesion (HSIL). Therapeutic vaccination with HPV-16 synthetic long peptide vaccine in women with vulvar intraepithelial neoplasia led to durable complete response in 47% of patients [77]. While this vaccine was tested in patients with advanced or recurrent HPV-16 positive gynecological carcinoma, no clinical benefit was observed despite generation of vaccine-induced HPV-16-specific T-cell responses [78]. Furthermore, adoptive T cell transfer of HPV-targeted tumor-infiltrating T cells in women with metastatic cervical cancer resulted in responses in three of nine patients with one partial and two complete responses [79].

Several types of therapeutics examined in trials have rendered varying levels of clinical benefit, which further declines in advanced carcinomas. Owing to several advantages of alphaviral vector vaccine platforms and in view of remarkable preclinical results, we initiated the first-in-human trial of Vvax001 in January 2017. The principal aim of the trial is to evaluate the safety and side-effects as well as immunological activity induced by Vvax001, a therapeutic viral vector vaccine encoding a fusion protein of HPV16-derived E6 and E7 oncoproteins. In this phase I study, four dose levels were tested, with three subjects per dose level. The study participants received three doses
of the vaccine via intra-muscular injection in an interval of 3 weeks. The side-effects of the vaccine were scored using common toxicity criteria grades. In order to monitor the immune responses, blood was collected at baseline as well as 7–10 days after second and third vaccinations. The immune responses induced by the vaccine were assessed in circulating blood following isolation of peripheral blood mononuclear cells (PBMCs). HPV-16-specific responses to vaccination are being evaluated by a set of immune monitoring assays including interferon-γ ELISPOT (Enzyme-linked ImmunoSpot), intra-cellular cytokine staining (ICS), phenotypic staining as well as proliferation for cell-mediated responses and ELISA (enzyme-linked immunosorbent assay) using serum to test for antibodies against the viral vector. The results of this first-in-human trial with a recombinant SFV replicon vaccine will be presented in the second half of 2018.

Conclusions and perspectives

Alphavirus-based vector systems have several advantages: (1) high heterologous gene expression; (2) induction of apoptosis resulting in cross-presentation of antigens; (3) induction of innate and adaptive immune responses and (4) lack of pre-existing immunity. The combination of all of these features in this vector system results in potent immune responses. We have developed therapeutic vaccines based on SFV vectors. These vaccines have been specially designed, taking into consideration their biosafety for use in humans. Immunization with rSFV induces potent anti-tumor immunity and long-term immune memory in mouse tumor models. The first-in-man trial of Vvax001 will give us further information on its safety, tolerability and immunogenicity in human subjects. On successful completion of the Phase I trial, we would like to evaluate the clinical efficacy of the vaccine with respect to regression of lesions in a Phase II trial. Based on knowledge of its tolerability and therapeutic efficacy in such clinical studies, this vaccine can be extended as a platform to other cancer types.

Combining different therapeutic strategies has emerged as a promising approach towards enhancing anti-tumor efficacy of cancer immunotherapy. Both radiation therapy and sunitinib and their combination can enhance the efficacy of cancer vaccines by modifying the tumor microenvironment supporting tumor eradication. The next approach would be to explore targeted therapies to combine with therapeutic vaccination. This approach will focus on the use of monoclonal antibodies blocking inhibitory checkpoint molecules and/or stimulating co-stimulatory molecules. Comprehensive studies would have to be conducted to attain combination strategies that have a synergistic effect in preclinical models that could be extended to further strengthen anti-tumor efficacy in clinical studies.

In conclusion, we demonstrated that recombinant SFV vectors serve as a suitable vector system for antigen delivery and the vector vaccines that we have developed provide a safe therapeutic tool to combat HCV- and HPV-related infections/malignancies.

Acknowledgements We are indebted to all technicians, previous post-docs and PhD students and all collaborators involved in the studies described in this review. We also thank collaborators of ViciniVax and the department of the Biotech Unit of the Pharmacy department of the University Medical Center Groningen (UMCG) involved in the generation of the clinical batch of Vvax001.

Author contributions AS composed and wrote the article. All authors contributed to the experimental work described, the discussion of the content and editing of the article.

Funding The studies described were made possible through several grants from the Dutch Cancer Society, RUG 2001–2361; RUG 2008–4066; RUG 2009–4549; RUG 2009–4579; RUG 2011–5156 and funding by the European Fund for Regional development (EFRO) project number 068/073.

Compliance with ethical standards

Conflict of interest Toos Daemen is founder of ViciniVax, a spin-off company of the UMCG, developing therapeutic cancer vaccines. All other authors declare that they have no conflict of interest.

Ethical approval and ethical standards All animal experiments reported in this article were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Groningen and were performed in accordance with the national and/or institutional guidelines for the care and use of animals. Clinical trial: Vvax001 FIH trial: NCT03141463. EudraCT Number: 2015-004979-74. Ethics committee: Centrale Commissie Mensegebonden Onderzoek (CCMO), The Netherlands. Institutional Review Board: Medical Ethical Committee (METc).

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Van de Wall S, Nijman HW, Daemen T (2014) HPV-specific immunotherapy: key role for immunomodulators. Anticancer Agents Med Chem 14:265–279
2. Skeate JG, Woodham AW, Einstein MH et al (2016) Current therapeutic vaccination and immunotherapy strategies for HPV-related
1. Liljeström P, Garoff H (1991) A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Nat Biotechnol 9:1356–1361
2. Pushko P, Parker M, Ludwig GV et al (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389–401. https://doi.org/10.1006/viro.1997.8878
3. Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S (1993) Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol 67:6439–6446
4. Jose J, Snyder JE, Kuhn RJ (2009) A structural and functional perspective of alphavirus replication and assembly. Future Microbiol 4:837–856
5. Quetglas JI, Ruiz-Guillen M, Aranda A et al (2010) Alphavirus RNA vaccines. Expert Rev Vaccines 10:981–993. https://doi.org/10.1586/14760584.2010.965690
6. MacDonald GH, Johnston RE (2000) Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 74:914–922. https://doi.org/10.1128/JVI.74.2.914-922.2000
7. Berglund P, Sjogren M, Garoff H et al (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389–401. https://doi.org/10.1006/viro.1997.8878
8. Ahi YS, Bangari DS, Mittal SK (2011) Adenoviral vector immunity and vaccine design. Nat Rev Microbiol 5:555–563. https://doi.org/10.1038/nrmicro1709
9. Tatsis N, Ertl HCJ (2004) Adenoviruses as vaccine vectors. Mol Ther 12:1410–1414. https://doi.org/10.1038/sj.gt.3302536
10. Riezebos-Brilman A, Regts J, Freyenschmidt EJ et al (2005) Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther 12:1410–1414. https://doi.org/10.1038/sj.gt.3302536
11. MacDonald GH, Johnston RE (2000) Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 74:914–922. https://doi.org/10.1128/JVI.74.2.914-922.2000
12. Huckriede A, Bungener L, Holtrup M et al (2004) Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine 22:1104–1113. https://doi.org/10.1016/j.vaccine.2003.10.003
13. Näslund TI, Kostic L, Nordström EKL et al (2011) Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol J 8:36. https://doi.org/10.1186/1743-422X-8-36
14. Ahi YS, Bangari DS, Mittal SK (2011) Adenoviral vector immunity and vaccine design. Nat Rev Microbiol 5:555–563. https://doi.org/10.1038/nrmicro1709
15. Osada T, Yang XY, Hartman ZC et al (2009) Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumventing pre-existing anti-vector immunity. Cancer Gene Ther 16:673
16. Ahl YS, Bangari DS, Mittal SK (2011) Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 11:307–320
17. World Health Organization (2018) Human papillomavirus (HPV) and cervical cancer. http://www.who.int/en/news-room/factsheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. Accessed 27 Aug 2018
18. Harper DM, DeMars LR (2017) HPV vaccines—a review of the first decade. Gynecol Oncol 146:196–204. https://doi.org/10.1016/j.ygyno.2017.04.004
19. Bruni L, Diaz M, Barrionuevo-Rosas L et al (2016) Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Heal 4:e453–e463. https://doi.org/10.1016/S2214-109X(16)30099-7
20. Bontkes HJ, de Gruijl TD, van den Muyzenberg AJC, et al (2000) Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 88:92–98. https://doi.org/10.1002/1097-0215(20001001)88:1<3C92::AID-IJC153>3.0.CO;2-E
21. Daemen T, Pries F, Bungener L et al (2000) Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 7:1859–1866. https://doi.org/10.1038/sj.gt.3301257
22. Sjogren EM, Suomalainen M, Garoff H (1994) A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Biotechnology 12:1127–1131
23. Daemen T, Regts J, Holtrup M, Wilshout J (2002) Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 and E7. Gene Ther 9:85–94. https://doi.org/10.1038/sj.gt.3301627
24. Daemen T, Riezebos-Brilman A, Bungener L et al (2003) Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 21:1082–1088. https://doi.org/10.1016/S0264-410X(02)00558-3
25. Riezebos-Brilman A, Regts J, Freyenschmidt EJ et al (2005) Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther 12:1410–1414. https://doi.org/10.1038/sj.gt.3302536
26. Dummer R, Hassel JC, Fellenberg F et al (2004) Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 104:1631–1638. https://doi.org/10.1182/blood-2004-01-0360
27. Dreno B, Urosevic-Maiwald M, Kim Y et al (2014) TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial. PLoS One 9:1–6. https://doi.org/10.1371/journal.pone.0083670
37. de Mare A, Lambeck AJA, Regts J et al (2008) Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition. Gene Ther 15:393–403. https://doi.org/10.1038/sj.gt.3303060
38. Walczak M, de Mare A, Riezebos-Brilman A et al (2011) Heterologous prime-boost immunizations with a virosomal and an aliphavirus replicon vaccine. Mol Pharm 8:65–77. https://doi.org/10.1021/mp1002043
39. Naslund TI, Uyttendove C, Nordstrom EKL et al (2007) Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J Immunol 178:6761–6769
40. Lin C-T, Hung C-F, Juang J et al (2003) Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing sindbis virus replicon particles. Mol Ther 8:559–566. https://doi.org/10.1016/S1525-0016(03)00238-7
41. Mennuni C, Calvaruso F, Facciabene A et al (2005) Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 117:444–455. https://doi.org/10.1002/ijc.21188
42. Harari A, Bart P-A, Zohr W et al (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T-cell responses. J Exp Med 205:63–77. https://doi.org/10.1084/jem.20071331
43. Rice J, Ottenmeier CH, Stevenson FK (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8:108–120. https://doi.org/10.1038/nrc2326
44. Oosterhuis K, Aleyd E, Vrijland K et al (2012) Rational Design of DNA Vaccines for the Induction of Human Papillomavirus Type 16 E6- and E7-Specific Cytotoxic T-Cell Responses. Hum Gene Ther 23:1301–1312. https://doi.org/10.1089/hum.2012.101
45. Ip PP, Boerma A, Walczak M et al (2015) Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. Gene Ther 22:560–567. https://doi.org/10.1038/nrc.2326
46. Daemen T, Riezebos-Brilman A, Regts J et al (2004) Superior therapeutic efficacy of aliphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 9:733–742
47. Oosterhuis K, van den Berg JH, Haanen JBAG et al (2014) Intradermal vaccination by DNA tattooing. In: Teunissen MBM (ed) Intradermal immunization. Springer, Berlin, pp 221–250
48. van den Berg JH, Oosterhuis K, Schumacher TNM et al (2014) Intradermal vaccination by DNA tattooing. In: Rinaldi M, Fioretti D, Iurescia S (eds) DNA vaccines: methods and protocols. Springer, New York, pp 131–140
49. Babiarova K, Kutinova L, Zurkova K et al (2012) Immunization of multiple myeloma cell lines and primary tumors. Vit Cell Dev Biol Anim 42:89–95. https://doi.org/10.1290/05080541
50. Poworoznyk P, Poláková I, Kindlová M et al (2009) Vaccination with aliphavirus replicon particles. Mol Ther 8:559–566. https://doi.org/10.1038/s41598-017-04547-2
51. van de Wall S, Walczak M, van Rooij N et al (2015) Tattoo delivery of a Semliki Forest virus-based vaccine encoding human papillomavirus E6 and E7. Vaccines 3:221–238. https://doi.org/10.3390/vaccines3030221
52. van de Wall S, Ljungberg K, Ip PP et al (2018) Potent therapeutic efficacy of an aliphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. Oncoimmunology 00:1–10. https://doi.org/10.1080/2162402X.2018.1487913
53. Abdulhaq S, Weiner DB (2008) DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 42:219–232. https://doi.org/10.1007/s12026-008-8076-3
54. Todorova B, Adam L, Culina S et al (2017) Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques. Sci Rep 7:1–11. https://doi.org/10.1038/s41598-017-04547-2
55. Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034. https://doi.org/10.1084/jem.192.7.1027
56. Oosterwegel MA, Greenwald RI, Mandelbrot DA et al (1999) CTLA-4 and T cell activation. Curr Opin Immun 294–300
57. Visser J, Nijman HW, Hoogenboom BN et al (2007) Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol 150:199–209. https://doi.org/10.1111/j.1365-2249.2007.03468.x
58. Zhou G, Drake CG, Levitsky HI (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107:628–636
59. Welters MJ, Kenter GG, Piersma SJ et al (2008) Induction of Tumor-Specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14:178–187. https://doi.org/10.1158/1078-0432.CCR-07-1180
60. Walczak M, Regts J, Van Oosterhout AJM et al (2011) Role of regulatory T cells in immunization strategies involving a recombinant alphavirus vector system. Antivir Ther 16:207–218. https://doi.org/10.3851/IMP1751
61. Draghiuc O, Nijman HW, Daemen T (2011) From tumor immunosuppression to eradication: Targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol. https://doi.org/10.1155/2011/439053
62. Chiriva-Internati M, Grizzi F, Pinkston J et al (2006) Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. Vit Cell Dev Biol Anim 42:89–95. https://doi.org/10.1290/05080541
63. Matsumura S, Wang B, Kawashima N et al (2008) Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181:3099–3107
64. Draghiuc O, Walczak M, Hoogenboom BN et al (2014) Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int J Cancer 134:859–872. https://doi.org/10.1002/ijc.28418
65. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. https://doi.org/10.1038/nri2506
66. Draghiuc O, Lubbers J, Nijman HW, Daemen T (2015) Myeloid derived suppressor cells—an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology 4:954829. https://doi.org/10.4161/21624011.2014.954829
67. Draghiuc O, Nijman HW, Hoogenboom BN et al (2015) Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology 4:1–11. https://doi.org/10.4161/2162402X.2014.989764
68. Draghiuc O, Boerma A, Hoogenboom BN et al (2015) A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology 4:1–9. https://doi.org/10.1080/2162402X.2015.1029699
69. Rice AE, Latchman YE, Balint JP et al (2015) An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor
regression and reduction in PD-L1 expression. Cancer Gene Ther 22:454–462. https://doi.org/10.1038/cgt.2015.40

70. Mkrtichyan M, Najjar YG, Raulfs EC et al (2011) Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 41:2977–2986. https://doi.org/10.1002/eji.201141639

71. Villarreal DO, Chin D, Smith MA et al (2017) Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity. Oncotarget 8:39117–39130. https://doi.org/10.18632/oncotarget.16605

72. Wecker M, Gilbert P, Russell N et al (2012) Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol 19:1651–1660. https://doi.org/10.1128/CVI.00258-12

73. Slovin SF, Kehoe M, Durso R et al (2013) A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 31:943–949. https://doi.org/10.1016/j.vaccine.2012.11.096

74. Bernstein DI, Reap EA, Katen K et al (2009) Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28:484–493. https://doi.org/10.1016/j.vaccine.2009.09.135

75. Morse MA, Hobeika AC, Osada T et al (2010) An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 120:3234–3241. https://doi.org/10.1172/JCI42672

76. Trimble CL, Morrow MP, Kraynyak KA et al (2015) Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386:2078–2088. https://doi.org/10.1016/S0140-6736(15)00239-1

77. Kenter GG, Welters MJP, Valentijn ARPM et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838–1847. https://doi.org/10.1056/NEJMoa081097

78. van Poelgeest MIE, Welters MJP, van Esch EMG et al (2013) HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 11:1–14. https://doi.org/10.1186/1479-5876-11-88

79. Stevanović S, Draper LM, Langhan MM et al (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus–targeted tumor-infiltrating T cells. J Clin Oncol 33:1543–1550. https://doi.org/10.1200/JCO.2014.58.9093